Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 14, Issue 6, Pages 492-501
Publisher
Informa UK Limited
Online
2013-06-13
DOI
10.4161/cbt.24343
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer
- (2011) Qing-Hua Liu et al. CANCER LETTERS
- Pim Kinase Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Triggered by Bcl-2 Family Inhibitor ABT-737
- (2011) J. H. Song et al. CANCER RESEARCH
- Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity
- (2011) Ying-Ying Wang et al. CANCER SCIENCE
- Roles of Pim-3, a novel survival kinase, in tumorigenesis
- (2011) Naofumi Mukaida et al. CANCER SCIENCE
- The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells
- (2011) D. Xu et al. CARCINOGENESIS
- The Pim Kinases: New Targets for Drug Development
- (2011) Ronan Swords et al. CURRENT DRUG TARGETS
- The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms
- (2011) Methvin Isaac et al. DRUG RESISTANCE UPDATES
- Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor
- (2011) Mustapha Haddach et al. ACS Medicinal Chemistry Letters
- Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma
- (2010) Carolin Reiser-Erkan et al. CANCER BIOLOGY & THERAPY
- Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
- (2010) Stephen Y. Lai et al. DRUG RESISTANCE UPDATES
- Why target PIM1 for cancer diagnosis and treatment?
- (2010) Nancy S Magnuson et al. Future Oncology
- PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
- (2010) L. Brault et al. HAEMATOLOGICA
- PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation
- (2010) M. Chang et al. MOLECULAR CANCER THERAPEUTICS
- Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation
- (2009) Jian Chen et al. AMERICAN JOURNAL OF PATHOLOGY
- Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells
- (2009) L. S. Chen et al. BLOOD
- Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
- (2009) S. M. Mumenthaler et al. MOLECULAR CANCER THERAPEUTICS
- Consensus transcriptome signature of perineural invasion in pancreatic carcinoma
- (2009) I. Abiatari et al. MOLECULAR CANCER THERAPEUTICS
- Pim-1 plays a pivotal role in hypoxia-induced chemoresistance
- (2009) J Chen et al. ONCOGENE
- Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells
- (2008) Ying-Yi Li et al. CANCER SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started